Purpose
Guide health care providers in determining recommended vaccines for each age group.
How to use the schedule
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 – By Age)
- Determine recommended interval for catch-up vaccination (Table 2 – Catch-up)
- Assess need for additional recommended vaccines by medical condition or other indication (Table 3 – By Medical Indication)
- Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
Birth to 15 Months
Legend
| Range of recommended ages for all children | Range of recommended ages for catch-up vaccination | Range of recommended ages for certain high-risk groups or populations | Recommended vaccination can begin in this age group | Recommended vaccination based on shared clinical decision-making | No Guidance/Not Applicable |
These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).
| Vaccine and other immunizing agents | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Respiratory syncytial virus  (RSV-mAb [Nirsevimab]) |
1 dose depending on maternal RSV vaccination status, See Notes | 1 dose (8 through 19 months), See Notes | |||||||||
| Hepatitis B (HepB) |
1st dose | ←2nd dose→ | ←3rd dose→ | ||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
1st dose | 2nd dose | See Notes | ||||||||
| Diphtheria, tetanus, & acellular pertussis (DTaP: <7 yrs) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | |||||||
| Haemophilus influenzae type b (Hib) |
1st dose | 2nd dose | See Notes | ←3rd or 4th dose, See Notes→ |
|||||||
| Pneumococcal conjugate (PCV15, PCV20) |
1st dose | 2nd dose | 3rd dose | ←4th dose→ | |||||||
| Inactivated poliovirus (IPV) |
1st dose | 2nd dose | ←3rd dose→ | ||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
See Notes | ||||||||||
| Influenza (IIV3, ccIIV3) |
1 or 2 doses annually | ||||||||||
|
Influenza (LAIV3) |
|||||||||||
| Measles, mumps, rubella (MMR) |
See Notes | ←1st dose→ | |||||||||
| Varicella (VAR) |
←1st dose→ | ||||||||||
| Hepatitis A (HepA) |
(See Notes) | ←2-dose series, See Notes→ | |||||||||
| Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) |
|||||||||||
| Human papillomavirus (HPV) |
|||||||||||
| Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See Notes | ||||||||||
| Meningococcal B (MenB-4C, MenB-FHbp) |
|||||||||||
| Respiratory syncytial virus vaccine (RSV [Abrysvo]) |
|||||||||||
| Dengue (DEN4CYD: 9-16 yrs) |
|||||||||||
| Mpox |
|||||||||||
18 Months to 18 Years
| Vaccine and other immunizing agents | 18 mos | 19-23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13-15 yrs | 16 yrs | 17-18 yrs | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory syncytial virus
(RSV-mAb [Nirsevimab]) |
1 dose (8 through 19 months), See Notes | ||||||||||||||||||||||||||
| Hepatitis B
(HepB) |
←3rd dose→ | ||||||||||||||||||||||||||
| Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series) |
|||||||||||||||||||||||||||
| Diphtheria, tetanus, & acellular pertussis
(DTaP: <7 yrs) |
←4th dose→ | 5th dose | |||||||||||||||||||||||||
| Haemophilus influenzae type b
(Hib) |
|||||||||||||||||||||||||||
| Pneumococcal conjugate
(PCV15, PCV20) |
|||||||||||||||||||||||||||
| Inactivated poliovirus (IPV)
|
←3rd dose→ | 4th dose | See Notes | ||||||||||||||||||||||||
| COVID-19 (1vCOV-mRNA, 1vCOV-aPS) |
See Notes | ||||||||||||||||||||||||||
| Influenza (IIV3, ccIIV3) |
1 or 2 doses annually | 1 dose annually | |||||||||||||||||||||||||
Influenza (LAIV3) |
1 or 2 doses annually | 1 dose annually | |||||||||||||||||||||||||
| Measles, mumps, rubella
(MMR) |
2nd dose | ||||||||||||||||||||||||||
| Varicella
(VAR) |
2nd dose | ||||||||||||||||||||||||||
| Hepatitis A
(HepA) |
← 2-dose series, See Notes→ | ||||||||||||||||||||||||||
| Tetanus, diphtheria, & acellular pertussis
(Tdap: ≥7 yrs) |
1 dose | ||||||||||||||||||||||||||
| Human papillomavirus
(HPV) |
See Notes | ||||||||||||||||||||||||||
| Meningococcal
(MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) |
See Notes | 1st dose | 2nd dose | ||||||||||||||||||||||||
| Meningococcal B
(MenB-4C, MenB-FHbp) |
See Notes | ||||||||||||||||||||||||||
| Respiratory syncytial virus vaccine
(RSV [Abrysvo]) |
Seasonal administration during pregnancy, See Notes | ||||||||||||||||||||||||||
| Dengue
(DEN4CYD: 9–16 yrs) |
Seropositive in endemic dengue areas (See Notes) | ||||||||||||||||||||||||||
| Mpox |
|||||||||||||||||||||||||||
- Determine recommended vaccine by age (Table 1 - By Age)
- Determine recommended interval for catch-up vaccination (Table 2 - Catch-up)
- Assess need for additional recommended vaccines by medical condition or other indication (Table 3 - By Medical Indication)
- Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
Additional Information
Report
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Helpful information
- Complete Advisory Committee on Immunization Practices (ACIP) recommendations
- ACIP Shared Clinical Decision-Making Recommendations
- General Best Practice Guidelines for Immunization (including contraindications and precautions)
- Vaccine information statements
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response)
Content Source:
National Center for Immunization and Respiratory Diseases